KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Evolent Health (EVH) FCF Margin (2016 - 2025)

Evolent Health has reported FCF Margin over the past 11 years, most recently at 8.76% for Q4 2025.

  • Quarterly results put FCF Margin at 8.76% for Q4 2025, up 1376.0% from a year ago — trailing twelve months through Dec 2025 was 0.25% (up 49.0% YoY), and the annual figure for FY2025 was 0.25%, up 49.0%.
  • FCF Margin for Q4 2025 was 8.76% at Evolent Health, up from 1.43% in the prior quarter.
  • Over the last five years, FCF Margin for EVH hit a ceiling of 23.92% in Q4 2021 and a floor of 25.16% in Q1 2021.
  • Median FCF Margin over the past 5 years was 0.66% (2022), compared with a mean of 0.22%.
  • Peak annual rise in FCF Margin hit 3151bps in 2021, while the deepest fall reached -2613bps in 2021.
  • Evolent Health's FCF Margin stood at 23.92% in 2021, then tumbled by -73bps to 6.52% in 2022, then surged by 130bps to 14.99% in 2023, then tumbled by -133bps to 5.01% in 2024, then skyrocketed by 275bps to 8.76% in 2025.
  • The last three reported values for FCF Margin were 8.76% (Q4 2025), 1.43% (Q3 2025), and 8.8% (Q2 2025) per Business Quant data.